|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,532 GBX | +2.08% |
|
+1.69% | +5.54% |
| 05:11pm | European Equities Traded in the US as American Depositary Receipts Fall in Wednesday Trading | MT |
| 10:20am | EU court criticizes Commission over handling of COVID vaccine contracts | RE |
(Reuters) - GSK beat market estimates for fourth-quarter profit and sales on Wednesday, underpinned by strong launch of its respiratory syncytial virus (RSV) vaccine Arexvy and steady demand for its shingles shot and HIV medicines.
The British drugmaker reported a profit of 28.9 pence per share on sales of 8.05 billion pounds ($10.20 billion), compared with analysts' average expectations of 28.63 pence profit on sales of 7.29 billion pounds, according to LSEG data.
($1 = 0.7892 pounds)
(Reporting by Eva Mathews in Bengaluru; Editing by Sherry Jacob-Phillips)
| 1st Jan change | Capi. | |
|---|---|---|
| +5.54% | 79.3B | |
| +57.09% | 848B | |
| +31.64% | 627B | |
| -0.82% | 363B | |
| +14.93% | 318B | |
| +12.19% | 299B | |
| +15.36% | 243B | |
| +16.77% | 225B | |
| +15.51% | 179B | |
| +3.59% | 167B |
GSK PLC 
